See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Biogen Inc. (BIIB) - free report >>
Johnson & Johnson (JNJ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Inc. (BIIB) - free report >>
Johnson & Johnson (JNJ) - free report >>
Image: Bigstock
Company News For August 29, 2017
· Shares of Expedia Inc. (EXPE - Free Report) declined 4.5% after the company’s Chief Executive Officer Dara Khosrowshahi announced that he would be joining Uber as CEO
· Biogen Inc.’s (BIIB - Free Report) shares surged 2.5% following positive results from an Alzhiemer’s drug study
· Shares of Gilead Sciences Inc. (GILD - Free Report) increased 1.2% after it entered into an agreement with Kite Pharma Inc. to acquire the company for a whopping $11 billion in cash
· Johnson & Johnson’s (JNJ - Free Report) shares increased almost 0.1% after it announced favorable results in a phase 3 study of its blood-thinning drug Xarelto